The members of the Prevention of Dementia using Mobile phone Applications (PRODEMOS) project announced the completion of the enrolment of research participants in its main study. The PRODEMOS study is a randomised controlled trial investigating the effect of the use of a coach-supported, interactive mHealth platform facilitating self-management of dementia risk factors in people in the UK and China. The first participant was recruited in the UK in January 2021. Participants are 55-75 years, are of low socio-economic status (UK) or from the general population (China), have ≥ 2 dementia risk factors, and use a smartphone. PRODEMOS is a hybrid implementation-efficacy study.
The main effectiveness outcome is change in dementia risk, measured with the CAIDE dementia risk score. Improvement of individual risk factors and cost-effectiveness will also be evaluated. Implementation outcomes include acceptability, adoption, feasibility, and sustainability of the intervention. The recruitment in the main PRODEMOS study was formally ended in April and the study succeeded in recruiting 600 participants in UK and 884 participants in China. The trial will run until April 2023 and the results will be published in an international peer-reviewed journal. The final aim of the PRODEMOS project is to implement the flexible, fully adaptable mHealth platform in a culturally appropriate form, in a range of healthcare settings across the globe. Further information on the PRODEMOS project can be found here: https://www.prodemos-project.eu/
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779238 and the National Key R&D Programme of China (2017YFE0118800).
